Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01371721 · ClinicalTrials.gov registry record · Phase 3
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 269
- Enrollment target
NCT01371721 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 269 participants.
The verdict
NCT01371721, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 269 participants
- Enrollment target
Study Summary
This is a 6-month, open-label, flexible-dose study evaluating desvenlafaxine succinate sustained release (DVS SR) in the treatment of child and adolescent outpatients with major depressive disorder (MDD).
Interventions
- DRUG DVS SR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 269 participants |
| Start Date | 2012-02 |
| Est. Completion | 2015-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01371721
The ClinicalTrials.gov registry entry for NCT01371721 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 269 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DVS SR is the first listed.
NCT01371721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01371721 about?
NCT01371721 is a clinical study titled "A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD". This is a 6-month, open-label, flexible-dose study evaluating desvenlafaxine succinate sustained release (DVS SR) in the treatment of child and adolescent outpatients with major depressive disorder (MDD).
What is the current status of trial NCT01371721?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 269 participants. The study started on 2012-02. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01371721?
The interventions under investigation include: DVS SR (DRUG).
Who is sponsoring clinical trial NCT01371721?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.